Santé raises $139M for med tech bets; Rox moves forward with hypertension trial;

@FierceMedDev: Varian Medical pays $35M to settle Pitt patent spat. News | Follow @FierceMedDev

@VarunSaxena2: ICYMI last week: Deerfield bets on robotic surgery with OMNIlife science deal. Article | Follow @VarunSaxena2

@EmilyWFierce: Staples wants to make 3D printing mainstream with a new trial program in New York and L.A. More from MedCity News | Follow @EmilyWFierce

@MichaelGFierce: ICYMI: 'Computer' made with DNA nanorobots delivers compounds in live cockroach. Story from FierceDrugDelivery | Follow @MichaelGFierce

> Med tech investor Santé Ventures has reportedly closed a $139 million new fund. Article

> Rox Medical has wrapped up enrollment in an international trial to test out its subcutaneous treatment for hypertension. News

> Syneron ($ELOS) picked up FDA clearance for its UltraShape device, a noninvasive technology for belly fat reduction. Release

Biotech News

@FierceBiotech: JNJ teams with Scripps on a new Big Pharma/biotech spinoff matchmaking effort. Story | Follow @FierceBiotech

@JohnCFierce: Cytos hits self-destruct button as PhIIb asthma study bombs. More | Follow @JohnCFierce

@DamianFierce: Two biotech/med tech IPOs expected this week in Vital Therapies and TriVascular Technologies. Item | Follow @DamianFierce

@EmilyMFierce: Essential immune organ regenerated in mice. More | Follow @EmilyMFierce

> Intercept grabs the spotlight at EASL, builds case for lead drug OCA. News

> Novartis slams the brakes on RNAi development efforts. Brief

> J&J axes a late-stage Botox rival, chopping project staffers. Story

Pharma News

@FiercePharma: Top-read FP news this weekend: PhRMA defends Gilead's pricey Sovaldi as docs look forward to more hep C choices. Story | Follow @FiercePharma

@TracyStaton: FiercePharma's best-read marketing story: Sanofi aims for outcomes with new Chief Patient Officer. More | Follow @TracyStaton

@EricPFierce: Daiichi Sankyo lays out the roadmap for finalizing the Ranbaxy and Sun deal. News | Follow @EricPFierce

@CarlyHFierce: Editor's Corner: Vivus needs more than boardroom shuffling to keep up with Arena's Belviq. Article | Follow @CarlyHFierce

> U.S. lawmakers join Lilly's attacks on Canada's patent attitude. News

> New attention disorder could equal a big new ADHD drug market. But is it legit? More

> Polish prosecutors hit GlaxoSmithKline with third round of bribery charges. Story

CRO News

> Clinipace cozies up to Karyopharm to get its pipeline moving. Story

> Parexel amps up its imaging focus in rebranded informatics biz. More

> Bristol-Myers enlists DKSH to push its drugs in Asia. Article

> Pacira picks Patheon to hit the gas on pain drug production. News

> Catalent inks a biosimilar alliance with a Chinese drugmaker. Report

> CROs are spending more on merit raises, survey says. Item

Biotech IT News

> PatientsLikeMe inks 5-year deal with Genentech. More

> Big Pharma companies open up cancer trial comparator arm data. Story

> Cheminformatics skills shortage threatens Indian drug discovery program. News

> Cancer foundation aiming to build a database of 50,000 human genomes. Report

> Pharma continues to grapple with trial participants' use of social media. Article

> NCI plans database of patients who experience miraculous recoveries. Item

Suggested Articles

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.